Phase I study of LOXL2 inhibitor in patients with Idiopathic pulmonary fibrosis
Phase of Trial: Phase I
Latest Information Update: 10 Mar 2017
At a glance
- Drugs LOXL2 protein-inhibitors (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Adverse reactions
- 10 Mar 2017 According to a Synairgen media release, company is planning to start this trial in H2 2017.
- 29 Mar 2016 New trial record
- 22 Mar 2016 According to Synairgen media this trial is expected to start during 2017.